Pediatric Hidradenitis Suppurativa Clinical Trials

Home | Studies | Pediatric Hidradenitis Suppurativa

Persistent Skin Bumps in Kids?

Explore New Treatment Options for Hidradenitis Suppurativa in Kids!

Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin condition that can significantly impact a child’s quality of life. The nodules are often inflamed, leading to painful lesions, abscesses, and scarring, primarily in areas such as the underarms, groin, and buttocks.

Revival Research Institute is conducting pediatric hidradenitis suppurativa clinical trials to explore potential treatment options that may help reduce symptoms and improve the quality of life for young patients.

To participate in the pediatric hidradenitis suppurativa clinical trials, your child must:

- Be at the age of 12 – 17 years
- Have been diagnosed with moderate to severe HS
- Have HS lesions in at least two distinct areas on the body

*Additional Criteria may apply

Despite its prevalence, limited treatment options are available for pediatric patients, making clinical research crucial in finding effective therapies. Revival Research Institute is working to evaluate innovative pediatric hidradenitis suppurativa treatment options.

About the Pediatric Hidradenitis Suppurativa Clinical Trials

We are conducting a Phase III open-label clinical trial to evaluate the safety and pharmacokinetics (PK) of investigational drug in children and adolescents (12-17 years) with moderate to severe Hidradenitis Suppurativa (HS).

The study is investigating a monoclonal antibody, that reduces inflammation and potentially improve HS symptoms. This trial aims to address the limited treatment options available for pediatric HS.

Eligible participants who enroll in the study will be asked to attend regular study visits, where they may undergo physical examinations, blood sample collection, and medical questionnaires. A team of experienced healthcare professionals will oversee your health and progress at every step. Participation in this clinical trial is completely voluntary.

*All study procedures and study-related treatments, including the investigational drug, are provided at no cost, and no insurance is required to participate.

*To take the next step, submit the form above, and our research staff will contact you to determine if you qualify for the study. A brief discussion about your health and medical history may be required.

Get Started: What to Expect?

Participation in the study may last up to 145 weeks. This study is being conducted as part of the development of bimekizumab for Hidradenitis Suppurativa (HS) in the pediatric population. It is a Phase 3, multicenter, open-label study to assess the pharmacokinetics (PK) and safety of bimekizumab in adolescents (12 to 17 years of age) and children ≥9 years of age with moderate to severe HS who are at Tanner stage 2 or more of pubertal development. If eligible, participants will receive the study drug, which will be administered weekly through a subcutaneous injection.

Throughout the study, a qualified research team will closely monitor participants’ health. Insurance is not required, and participants may receive compensation for time and travel. Participation is entirely voluntary, and all questions will be addressed during the informed consent process.

Condition

Hidradenitis Suppurativa

Location

Troy, Michigan

Age

12 to 17 years of age

Hidradenitis Suppurativa: The Painful Confidence Crusher

Pediatric Hidradenitis Suppurativa (HS) presents as painful inflamed nodules, abscesses, pus-discharging tracts, and fistulas in skin-fold areas such as:

Armpits (axillary region)
Groin (inguinal region)
Gluteal and perineal areas

The condition can significantly impact confidence and quality of life due to severe pain, movement restriction, and foul-smelling discharge.

HS is linked to genetic predisposition, smoking, obesity, and hormonal factors. Managing HS remains challenging, often requiring a combination of medical and surgical approaches. Current treatments include topical therapies, systemic antibiotics, hormonal therapies, and immunosuppressants. However, resistance to conventional treatments highlights the need for potential treatment options to improve patient outcomes.

Frequently Asked Questions

What is Hidradenitis Suppurativa (HS)?

Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition that leads to painful, pus-filled nodules, abscesses, and tunnels, commonly affecting areas such as the armpits, groin, buttocks, and under the breasts. The condition can have a profound impact on both physical health and emotional well-being.

What causes Hidradenitis Suppurativa?

The exact cause of HS remains unclear, but it is believed to result from a combination of genetic predisposition, immune system dysfunction, and environmental factors. Lifestyle habits such as smoking, obesity, and hormonal imbalances may also contribute to symptom flare-ups. Blocked hair follicles and excessive inflammation play a significant role in the development of this condition.

How can Hidradenitis Suppurativa be treated?

While there is no definitive cure for HS, several treatment approaches can help manage symptoms and reduce flare-ups:

Medical treatments: Doctors may prescribe antibiotics, biologics, anti-inflammatory medications, or hormonal therapy to help control the condition.
Hygiene practices: Gently cleansing affected areas with mild soap and warm water can help prevent irritation.
Warm compresses: Applying warm compresses may help alleviate pain and encourage abscess drainage.
Weight management: Maintaining a healthy weight through proper diet and regular physical activity may improve symptoms.
Wound care: Properly cleaning and dressing wounds can minimize infection risks and promote healing.
Stress management: Managing stress through meditation, therapy, or relaxation techniques may help reduce flare-ups.
Clothing choices: Wearing loose-fitting, breathable fabrics can help reduce irritation in affected areas.

Because HS affects individuals differently, it is important to consult a healthcare provider for a personalized treatment plan.

How long will the clinical trial last?

The Hidradenitis Suppurativa clinical trial is expected to last approximately 145 weeks. Before enrolling, participants will receive a detailed study overview, including the duration, required visits, and study procedures.